TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimer’s Association International Conference (AAIC®) to be held July 26-30, 2021 in Denver, USA and online.
ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: “Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.” Dr. Cashman will deliver this presentation and chair the Virtual Oral Session #55269 to be held on Thursday, July 29, from 1:00 PM – 2:15 PM MT.
Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: “Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.” The poster discusses conformational epitopes on misfolded proteins that represent unique targets for therapeutic antibodies. Dr. Kaplan will deliver her poster presentation in person in Denver and online. Please consult the AAIC® website (https://alz.org/aaic/overview.asp) for venue, date and time of the presentation.
Both presentations will be available on the ProMIS website (www.promisneurosciences.com) after the AAIC® closes on July 30.
AAIC® is the largest, most influential international meeting focused on advancing dementia science. The annual conference convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care community to share research discoveries supporting new methods of prevention, treatment and diagnosis of Alzheimer’s disease.
About the ProMIS Pipeline
ProMIS Neurosciences’ lead therapeutic candidate, PMN310, is a monoclonal antibody for Alzheimer’s disease created with a novel, proprietary method for discovering and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins. PMN310 selectively targets the toxic oligomeric species of amyloid beta (Aß), a root cause of Alzheimer’s disease. Preclinical studies show that PMN310 demonstrates a high degree of binding to toxic oligomers as opposed to non-toxic forms of Aß, possessing greater selectivity versus other Aß-directed antibodies. ProMIS has also developed antibody candidates that demonstrate high selectivity for the toxic species of other proteins in the brain, including antibody candidates for Parkinson’s disease that show best-in-class selectivity for toxic forms of alpha-synuclein, and antibody candidates for ALS that selectively target the toxic form of TDP-43.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.